Read Summary

The agency has approved the combination of tremelimumab (Imjudo) and durvalumab (Imfinzi) for use together with chemotherapy for patients with metastatic non–small cell lung cancer (mNSCLC).
FDA Approvals

Print Friendly, PDF & Email